Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-principle study of Liproca Depot (2-hydroxyflutamide) injected into the prostate in localized prostate cancer
2009-010079-25Phase 2Completed
- Sponsor
- LIDDS AB
- Start
- Mar 2009
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 2-hydroxyflutamide depot in prostate cancer (PCa), sponsored by LIDDS AB. Primary endpoint: PSA nadir. Started Mar 2009; status: completed.
02
Drugs
2-hydroxyflutamide depot
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-010079-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010079-25.